medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2000, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2000; 47 (1)

HER-2/neu proto-oncogen amplification related to low risk VPH infection in cervical exfoliative cytology

Abba MC, Mourón SA, Güerci A, Gómez MA, Dulout FN, Golijow CD

Language: Spanish
References: 23
Page: 26-31
PDF size: 139.38 Kb.


ABSTRACT

Sixty-nine non-cancerous cytological samples from exocervical specimens positives for HPV type-6, -16 and -18, and 24 non-infected samples as controls were analyzed for HER-2/neu gene amplification. The genomic differential polymerase chain reaction with the single copy reference gene was employed for gene amplification detection. An association between HER-2/neu gene amplification and "low-risk" HPV group (type-6) was found (p ‹ 0.005). Within this group, HER2/neu amplification was associated to the CIN I grade (p ‹ 0.01). Since, in the samples analyzed most of the CIN I stage was characterized by a koilocitotic pattern, HER-2/neu amplification could be related to this kind of cellular alteration. It would be important the study of HER-2/neu gene amplification and also gene expression in different CIN stages, in order to determine its role and significance in cervical carcinogenesis.


REFERENCES

  1. Zur Hausen H. Human papillomavirus in the pathogenesis of anogenital cancer. Virology 1991; 184: 9-13.

  2. Parkin D, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594.

  3. Boring CC, Squires TS, Tong T, Montgomery S. Cancer Statistics. CA Cancer J Clin 1994; 44(1): 7-26.

  4. Gissman L. Human Papillomavirus and genital cancer. Semin Cancer Biol 1992; 3: 253-261.

  5. Ross D. Introduction to oncogenes and molecular cancer medicine. Ed Word Crafters. Springer Press, New York. 1998.

  6. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999; 26(4): 51-59.

  7. Bahman S, Jones LA, El-Naggar A, Felix JC, George J et al. Amplification and overexpression of HER-2/neu (c-erbB-2) in endometrial cancers: correlation with overall survival. Cancer Res 1995; 55: 5693-5698.

  8. Medl M, Sevelda P, Doz MD. DNA amplification of HER-2/neu and INT-2 oncogene in epithelial ovarian cancer. Gynecol Oncol 1995; 59: 321-326.

  9. Depowski PL, Brien TP, Sheehan CE, Stylos S, Johnson RL et al. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. Am J Clin Pathol 1999; 112(4): 459-469.

  10. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant lung epithelial cells. Int J Cancer 1999; 83(4): 564-570.

  11. Oh JJ, Grosshans DR, Wong SG, Slamon DJ. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 1999; 27(20): 4008-4017.

  12. Roland PY, Stoler MH, Broker TR, Chow LT. The differential expression of the HER-2/neu oncogene among high-risk human papillomavirus-infected glandular lesions of the uterine cervix. Am J Obstet Gynecol 1997; 177(1): 133-138.

  13. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999; 5(3): 577-586.

  14. Ting Y, Manos MM. Detection and typing of genital human papillomavirus. In: Innis MA, Gelfant DH, Sneinsky JJ and White TJ (eds). PCR Protocols. Academic Press, San Diego 1990: 356-367.

  15. Evander M, Edlund K, Bodun E. Comparison of a one-step and two-step polymerase chain reaction with the degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol 1992; 30: 987.

  16. Drut R, Drut RM, Gómez MA, Lojo MM. Presence of human papillomavirus in extrahepatic biliary atresia. JPGN 1998; 27: 530-535.

  17. Lönn U, Lönn S, Nylén U. Gene amplification detected in carcinoma cells from human urinary bladder washings by the Polymerase Chain Reaction Method. Cancer 1993; 71: 3605-3610.

  18. Tiwari RK, Borgen PI, Wong GY. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992; 12: 419-425.

  19. Underwood M, Bartlett J, Reeves J. c-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995; 55: 2422-2430.

  20. Mitra AB, Murty VS, Pratap M. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994; 54: 637-639.

  21. Barbosa MS. The oncogenic role of Human Papillomavirus proteins. Critical Reviews in Oncogenesis 1996; T1-18.

  22. Scheffner M, Werness BA, Huibregtse JM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degeneration of p53. Cell 1990; 63: 1129-1136.

  23. Golijow CD, Mourón SA, Gómez MA, Dulout FN. Differences in K-ras codon 12 mutation frequency between “high-risk” and “low-risk” HPV infected samples. Gynecol Oncol 1999; 75(1): 108-112.




2020     |     www.medigraphic.com